title: [Cancer vaccine].
abstract: The existence of anti-tumor immune system has been reported and was proved by many experiments. A lot of tumor specific antigens as a target of immune system were identified and some have been applied for cancer vaccine. Since NY-ESO-1, one of cancer-testis antigens, was reported to be expressed frequently in cancers and to possess strong immunogenicity, it is also used for worldwide cancer vaccine trials. We have performed a cancer vaccine clinical trial with NY-ESO-1 protein and observed NY-ESO -1 specific immune responses in most of patients vaccinated. Some patients showed preferable clinical responses. Cancer vaccine was developed rapidly in the last decade, however there still left several problems to be resolved for the spread of cancer vaccine.
authors.affiliation: Department of Surgery, Osaka University, Graduate School of Medicine.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Wada
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nakayama
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008565:Membrane Proteins / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008565:Membrane Proteins